cyrilzakka/clinical-trials huggingface dataset:
Correlation Between Postoperative Pain and Apical Extrusion of Different Irrigation Activation Techniques

The aim of this clinical trial is :

To evaluate effect of different techniques of irrigant activation:

1. LASER activation
2. sonic activation
3. ultrasonic activation
4. passive needle irrigation

On:

1. Postoperative pain in vital teeth (Randomized controlled trial)
2. Amount of apical extrusion (In vitro study) Participants will describe their preoperative pain and postoperative pain level at fixed time interval Research will compare postoperative pain accompanied with different irrigant activation techniques and correlate it to amount of debris extrusion


Eligibility Criteria:
Inclusion Criteria:

* Age group 18-50 years
* Males and females
* Lower molars with symptomatic irreversible pulpitis without apical periodontitis

Exclusion Criteria:

* Patients with uncontrolled health conditions
* Immunocompromised patients
* Teeth with periodontal diseases
* Teeth with calcified canals
* pregnant patients
Effect of PEEP on Intraoperative Hypothermia

Intraoperative hypothermia is associated with many clinical adverse outcomes. Many techniques were applied to prevent intraoperative hypothermia, and positive end-expiratory pressure (PEEP) has been known to blunt intraoperative hypothermia by increasing thermoregulatory vasoconstriction threshold. The investigators assessed the effect of PEEP on the prevention of intraoperative hypothermia during spine surgery in prone position.

It is well known that intraoperative hypothermia is associated with postoperative adverse clinical outcomes in various study populations. Intraoperative hypothermia has various adverse effects including impaired drug clearance, cold diuresis and hypovolemia, immunosuppression with increased infection risk, electrolyte disorders, coagulopathy with impaired platelet function, negative nitrogen balance, shivering, insulin resistance, and myocardial events. Numerous methods have been introduced to prevent intraoperative hypothermia, such as warming of infusion fluid, forced-air warming, heat-pads, heated water mattress, and heated humidifiers. However, in patients undergoing lumbar spine surgery in the prone position, these methods to prevent intraoperative hypothermia may partially effective because these methods, in clinical practice, have a significant limitation in their application.

Positive end-expiratory pressure (PEEP) reduces the venous return by increasing intrathoracic pressure. This causes carotid unloading, which leads to a secondary peripheral vasoconstriction by increasing thermoregulatory vasoconstriction threshold and blunts intraoperative hypothermia. Previous studies demonstrated that intraoperative PEEP significantly attenuated the extent of intraoperative hypothermia in patients undergoing tympanoplasty. However, the beneficial effect of PEEP on thermoregulation is not investigated in patients with the prone position for spinal surgery.

The investigators hypothesized that PEEP can reduce the extent of intraoperative hypothermia via thermoregulatory modulation. In this study, the investigators investigated the effect of PEEP on intraoperative core body temperature and the incidence of intraoperative hypothermia in patients undergoing spinal surgery

Eligibility Criteria:
Inclusion Criteria:

* Patients who were scheduled for elective spine surgery requiring more than 3 hours

Exclusion Criteria:

* Patients who do not agree to the study
* Patients with or American Society of Anesthesiologists (ASA) physical status class 3 or more
* Patients with thyroid disease, peripheral vascular diseases, uncontrolled diabetes or hypertension
* Patients with morbid obesity (BMI \>35 kg/m2)
* Patients with clinically severe pulmonary disease
* Patients undergoing simultaneous anterior and posterior lumbar fusion surgery were also excluded.
* Patients with taking non-steroidal anti-inflammatory drug within two weeks
* Patients with preoperative fever or hypothermia
* Patients with intraoperative intentional hypothermia for neuroprotection
Autism and Attachment. An Explorative Study of Attachment Styles in Autistic Adults.

The present study examines the relationship between attachment and autism spectrum disorder (ASD) in adults.

Rationale: Previous research on autism spectrum disorder (ASD) and attachment has improved understanding of the aetiology and development of the disorder. Research on adults with ASD, however is scarce. The study is focussed on attachment in adults with ASD. Objective: The aim of the current study is to explore attachment styles of adults with ASD and examining the relationship between attachment and ASD.

The study requires 60 participants.

Eligibility Criteria:
Inclusion Criteria:

* Inclusion criteria are:

  * a primary clinical diagnosis of DSM-5 ASD (APA, 2013)
  * age 18 - 65 years
  * no intellectual disability (IQ \> 80)

Exclusion Criteria:

* acute psychosis
* acute suicidality
* psychotic disorder
* intellectual disability (IQ \< 80)
A Study of Cemdisiran in Adults With Immunoglobulin A Nephropathy (IgAN)

The purpose of this study is to evaluate the effect of cemdisiran on proteinuria in adults with immunoglobulin A nephropathy (IgAN), who excrete \>1 gram (gm) of protein per day despite standard of care, which includes treatment with angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARB). These participants are at high risk for progression of kidney disease, which can result in end-stage renal failure.


Eligibility Criteria:
Inclusion Criteria:

* Diagnosed with primary IgAN
* Currently being treated for IgAN with stable, optimal therapy, including an ACE inhibitor or ARB.
* Has urine protein greater than or equal to 1 gram/24-hour
* Has hematuria (blood cells present in urine)

Exclusion Criteria:

* Has renal disease other than IgAN
* Has a diagnosis of rapidly progressive glomerulonephritis
* Has a diagnosis of Henoch-Schonlein Purpura (IgA Vasculitis)
* Has poor kidney function with estimated glomerular filtration rate (eGFR) \<30 milliliters per minute per 1.73 meters square (mL/min/1.73 m\^2)
* Has known human immunodeficiency virus (HIV) infection, hepatitis C virus (HCV) infection or hepatitis B virus (HBV) infection
* Has on-going high blood pressure
* Treated with systemic corticosteroids for more than 7 days, or other immunosuppressant agents in the past 6 months
* Received an organ transplant
Compassionate Use of Omegaven in Children

This is a single-assignment study to evaluate whether Omegaven (IV fish oil) is effective at treating liver disease in children on long-term IV nutrition.

Children up to 18 years of age, on parenteral nutrition, with a direct bilirubin level of 2 mg/dL or greater will be eligible to receive Omegaven at a maximum dose of 1 g/kg/day.

Up to 200 children will be eligible for enrollment.

Direct bilirubin levels and other labs will be monitored as well as growth parameters.

Eligibility Criteria:
Inclusion Criteria:

* Live in or temporarily relocate to Oklahoma
* Age less than 18 years, both sexes, all races
* Have a direct bilirubin level of ≥2 mg/dL for two consecutive weeks after at least 14 days of parenteral nutrition
* Received parenteral lipids at a maximum dose of 1.7 g/kg/day (24 g/kg over the two weeks prior)
* Are not currently enrolled in another lipid emulsion study

Exclusion Criteria:

* Known food allergy to fish
* Known metabolic disorder of lipid metabolism
* Active coagulopathies (active bleeding or requiring blood product treatment in the prior 48 hours)
* Medical condition likely to result in death in the next 30 days
Eval. of Safety and Effectiveness of the FMwand Ferromagnetic Surgical System During Total Mesorectal Excision Surgery

The objective of the clinical trial is to determine the suitability of the FMwand Ferromagnetic Surgical System for Total Mesorectal Excision Surgery.


Eligibility Criteria:
Inclusion Criteria:

* Confirmed rectal cancer to the lower two-thirds of the rectum (higher and T2 N0 or N+)
* Amenable for standard surgery procedures using electrocautery, argon beam, lasers or other conventional tissue removal modalities
* ECOG status ≤ 2
* Life expectancy \>3 months
* Age ≥ 18 years old
* Age ≤ 80 years old
* Ability to provide written informed consent and HIPAA forms prior to admission to this study
* Willingness to meet all of the expected requirements of this clinical protocol

Exclusion Criteria:

* Patient with metastasis
* History of radiotherapy or chemotherapy for the treatment of rectal cancer
* Uremia - BUN\>40
* Hemodialysis
* Existing urinary or fecal incontinence
* Pregnant or lactating
* Previously diagnosed coagulopathy or bleeding diathesis
* Currently, or within the previous 10 days prior to surgery, taking any medications that would produce bleeding diathesis including but not limited to, Plavix, warfarin, NSAIDs, clopidogrel, ticlopidine or valproic acid
* History of significant cardiac disorders that would necessitate special fluid management protocols
* History of acute myocardial infarction and/or acute angina
* INR \>1.4 in the 24 hours prior to surgery
* PTT \>40 in the 24 hours prior to surgery
* Platelet count \<100K in the 24 hours prior to surgery
Is Harvesting the Peroneus Brevis an Alternative in Anatomic Ankle Ligament Reconstruction

Severe ankle sprains are the most frequent reason for emergency trauma consultations. Between 30% and 80% of sprains result in sequelae such as pain, joint derangement or instability. Ankle instability can itself lead to osteoarthritis if left untreated (1st cause of post-traumatic ankle osteoarthritis). To treat instability, ligament reconstruction is performed by harvesting the tendon of the gracilis muscle (inserted at knee level) to replace the damaged ankle ligaments. This tendon is also used for other ligament reconstructions (anterior cruciate ligament), so is not always harvested. Moreover, it represents an invasive procedure at a distance from the site of interest (the ankle), and can cause sensory nerve damage (20-60% of cases). For a long time, half of the peroneus brevis tendon was harvested as part of a now-defunct ankle stabilization technique (Hemi-Castaing). This tendon does, however, play a role in stabilizing the ankle.

Before considering harvesting the peroneus brevis as an alternative to harvesting the gracilis, it is important to ensure that the peroneus brevis remains functional after harvesting. The aim of this study was to evaluate the potential for tendon regrowth after harvesting half of the peroneus brevis tendon after Hemi-Castaing-type ankle stabilization surgery.

Eligibility Criteria:
Inclusion Criteria:

* Adult one year after peroneus brevis harvesting (Hemi-Castaing)

Exclusion Criteria:

* No.
Intravenous Autologous Mesenchymal Stem Cells Transplantation to Treat Middle Cerebral Artery Infarct

This study aims to determine the efficacy of intravenous transplantation of autologous bone marrow-derived mesenchymal stem cells in patients with acute middle cerebral artery infarct.


Eligibility Criteria:
Inclusion Criteria:

* Experiences stroke onset within 2 weeks to 2 months
* NIHSS score of \>10-35
* Never received or failed thrombolysis
* Evidence of unilateral middle cerebral artery infarct on brain MRI

Exclusion Criteria:

* Medically unfit (eg. those are unstable haemodynamically despite treatment, with worsening conscious level and with other serious medical co-morbidity)
* Evidence of any tumor or other space-occupying lesion on brain MRI
* Evidence of hemorrhagic stroke on brain CT or MRI
* Experiences transient ischemic attack or lacunar infarct
* Has any acute or chronic infections such as Hepatitis B, Hepatitis C and HIV
* Is diagnosed with concurrent malignancy or primary hematological disorders
* Renal impairment indicated with serum creatinine greater than 200 umol/l or creatinine clearance less than 30 ml/min
* Liver impairment indicated with serum aspartate transaminase and serum alanine transaminase greater than 4 times upper limit of the normal range
* Any contraindication to stem cell transplantation or bone marrow biopsy
* Any co-morbidity which will compromise the ability to obtain adequate stem cells (eg. chronic debilitating diseases, frail patients and patients with known osteoporosis)
* Any contraindication to brain MRI (eg. metal implants, pacemaker, joint implants and ocular implants)
PECS II Versus ICBN Block Plus SCNB for AV Fistula Creation in CRF Patients

Brachial plexus block (BPB) is often utilized for proximal arm arteriovenous access creation. However, the medial upper arm and axilla are often inadequately anesthetized, as the Intercostobrachial nerve (which provides sensory supply to the axilla, upper medial arm, and a small area at the upper lateral chest) is not a component of the brachial plexus. This requires repeated, an intraoperative local anesthetic (LA) supplementation up to conversion into GA. The intercostobrachial nerve (ICBN) is a purely sensory nerve that arises primarily from the second intercostal nerve (T2) with occasional contribution from T3. Therefore, It is not a component of the brachial plexus and is not anesthetized by brachial plexus blockade. The ICBN can be blocked together with other nerves, such as the pectoral, intercostal, and long thoracic nerves in a recently described technique named pectoral nerves block type II (PECS II ).In this thesis, investigators compared the use of the PECS II block and ICBN block as a supplement to supraclavicular brachial plexus block for providing complete anesthesia of the upper arm for fistula creation surgery.


Eligibility Criteria:
Inclusion Criteria:

* ESRD patients.
* Proximal Arm Arteriovenous Access Surgery.
* Elective or emergency surgery
* American Society of Anesthesiology (ASA) physical status II to III.

Exclusion Criteria:

* Inability of the patient to provide informed consent, communicate or cooperate
* History of allergy to local anesthetics.
* Preexisting upper limb neurological disease at the side of the surgery.
* Patients on anticoagulant therapy or with history of coagulopathy.
* Previous surgery at or near the site of the study.
* The presence of skin infection at the puncture site.
Awake Prone Positioning and Oxygen Therapy in Patients With COVID-19

The prone position strategy for patients with acute respiratory distress syndrome (ARDS) is simple and cost-effective from the first description on its use in patients with acute respiratory failure to improve hypoxemia. Different studies have investigated its safety and efficacy in various clinical settings, demonstrating that its early use in combination with non-invasive mechanical ventilation (NIV) or high-flow oxygen therapy can reduce intubation rate and mortality in ARDS. In the Coronavirus disease 2019 (COVID-19) pandemic, high-value medicine and resource optimization are critical.

Coronavirus disease 2019 (COVID-19) is a pandemic that has significantly challenged health systems worldwide. Due to the large number of infections around the world, the implementation of strategies to reduce the number of intubations and the need for invasive mechanical ventilation becomes important. In addition to the inability of the Mexican health system to respond, patients under invasive ventilation have not had a favorable survival outcome. Up to 97% mortality has been reported in patients requiring intubation. The exact cause of this poor prognosis is not yet known. Early recognition of hypoxemic patients could help with the results. It seems reasonable in these patients to perform procedures to improve the clinical respiratory picture before intubation in less severe cases due to the aforementioned. Prone patient placement during invasive mechanical ventilation is a widespread practice in the management of severe ARDS of other etiologies. Currently, few attempts have been made to implement the prone position in patients who spontaneously ventilate with supplemental oxygen, high-flow nasal cannulas, or noninvasive mechanical ventilation. Taking into account that it is a procedure that does not require additional infrastructure within the services and does not represent an additional cost for its implementation, it becomes a valuable tool in the context of COVID-19 where intubation is associated with high mortality and in a Additionally, there are mechanical ventilator deficits in most hospitals. This work has feasibility to be carried out because it will be carried out in critical areas that have equipment and trained personnel for it in the different shifts, in addition to having patients diagnosed with COVID-19.

Eligibility Criteria:
Inclusion criteria

* Patient records with the following characteristics:
* Patients over 18 years of age
* Patients of both genders
* Patients diagnosed with COVID-19 infection
* Patients admitted to hospital
* Complete file

Non-inclusion criteria • Patients who do not decide to participate in the study

Exclusion criteria

• Files not found.

Elimination criteria

* Files with incomplete data
* File with a voluntary discharge or transfer note.
Effect of Foot Muscle Energy Technique in Patients With Diabetic Neuropathy

Foot muscle energy technique and conventional physical therapy program administered in patients with type 2 Diabetic Neuropathy.

Foot muscle energy technique and conventional physical therapy program administered in patients with type 2 Diabetic Neuropathy.

Eligibility Criteria:
Inclusion Criteria:

* Participants (males and females) examined with non-insulin-dependent diabetes for ≥10 years determined by neurophysiological measurements were enrolled.
* The participants regularly took their diabetes medications during the assessment and treatment period.
* The use of any sedatives or anticonvulsants was contraindicated for all participants.

Exclusion Criteria:

• Uncontrolled non-insulin dependent diabetes and diagnosed for \< 10 years, neural, muscular, and skeletal system deformities; radiculopathy; and psychiatric disorders.
PASS OCT® Post-market Clinical Follow-up

Prospective, multicenter non comparative and observational study (post-market clinical follow-up).

Patients operated with PASS OCT® manufactured by MEDICREA® INTERNATIONAL between July 2016 and July 2017.

The inclusion period will be 12 months and the follow-up 24 months

The primary endpoint is to evaluate the safety of the PASS OCT® system.

The secondary endpoints are to analyze the efficacy of the system with several point of view:

* The quality of fusion and the time of fusion through X rays
* the pain with VAS
* the quality of life thanks to questionnaires: NDI (Neck Disability Index) and JOA for myelopathy
* the daily of the patient: return to work, sport
* the surgeon satisfaction.

Eligibility Criteria:
Inclusion Criteria:

* Patient with

  * degenerative disc disease or,
  * spondylolisthesis, or
  * spinal stenosis, or
  * trauma, or
  * atlanto-axial fractures with instability or
  * cervical tumors.
* Patient operated with PASS OCT®
* Patient \> 18 years
* Patient affiliated to health care insurance (social security in France)
* Patient able to complete a self-administered questionnaire
* Patient able to understand the protocol and the planning visit
* Patient able to sign an informed consent form

Exclusion Criteria:

* Patient unable or unwilling to sign an informed consent form
* Patient unable to complete a self-administered questionnaire
* Pregnant patient or intending to get pregnant within the next 3 years
* Patient judged as non-compliant by the investigator or not able to come back for follow-up visits
Phase 1/2 Study of ZN-d5 for the Treatment of Relapsed or Refractory Light Chain (AL) Amyloidosis

This is a single arm, Open-Label, Phase 1/2 Study of ZN-d5 for the Treatment of Relapsed or Refractory Light Chain (AL) Amyloidosis.

A Single Arm, Open-Label, Phase 1/2 Study of ZN-d5 for the Treatment of Relapsed or Refractory Light Chain (AL) Amyloidosis. The first part of the study is phase 1 dose-escalation and the second part will be phase 2.

Eligibility Criteria:
Key Inclusion Criteria:

1. Diagnosis of AL amyloidosis based on histopathology, the presence of characteristic appearance on electron microscopy, or mass spectrometry typing of amyloid.
2. Prior AL amyloidosis treatment and has received at least one, but no more than three lines of prior therapy;
3. At least 3 months from hematopoietic stem cell transplantation or the shorter of 60 days or 5 half-lives for biologics, small molecules, or investigational drugs prior to starting treatment;
4. Measurable disease defined by serum differential free light chain;
5. Assessment of t(11,14) status by FISH;
6. Eastern Cooperative Oncology Group performance status ≤2 ;
7. History of organ involvement
8. Adequate bone marrow function prior to first administration of study drug;
9. Adequate organ function;

Key Exclusion Criteria:

1. Presence of non-AL amyloidosis, including wild-type or mutated ATTR amyloidosis;
2. Diagnosis of multiple myeloma according to the 2014 International Myeloma Working Group diagnostic criteria;
3. Mayo 2012 Stage IV disease;
4. Cardiac involvement exclusions apply to some subjects, including heart failure and cardiac arrhythmias.
5. Prior treatment with other BCL-2 inhibitors;
BreEStim and tDCS for Neuropathic Pain Management - Healthy Subjects

This study looks at the effect of combined breathing-controlled electrical stimulation (BreEStim) and transcranial direct current stimulation (tDCS) on neuropathic pain after spinal cord injury, amputation, or brain injury. The hypothesis is that a single session of combined BreEStim and tDCS will produce an additive analgesic effect. This record covers the study in a population of healthy volunteers. Note that this study will also enroll spinal cord injury patients, brain injury patients, and amputation patients and that this study as applied to these other populations will be covered in separate ClinicalTrials.gov records.


Eligibility Criteria:
Inclusion Criteria:

* between 18 and 75 years
* male and female subjects
* healthy subjects (i.e., no recent injuries or pain)

Exclusion Criteria:

* recent injuries or pain
* have a pacemaker, or other metal and/or implanted devices
* have amputation in their arm(s)
* have spinal cord injury (SCI) involving impairment of arms
* have cognitive impairment from brain injury or are not able to follow commands, or to give consent
* have asthma or other pulmonary disease
* are not medically stable
* have preexisting psychiatric disorders
* alcohol or drug abuse
* have a history of seizures/Epilepsy, or taking benzodiazepines, anticonvulsants, and antidepressants.
* Mini-mental state examination (MMSE), a brief 30-point questionnaire test that is commonly used in the literature, will be used to screen for cognitive impairment. A brain injury patient with a score of 24 or lower on MMSE will be excluded.
Impact of a Cueing Device on Upper Extremity Muscle Strength in Swimmers

The goal of this study is to find out if a tool called an external cueing device (ECD) can help young swimmers improve their shoulder function. An ECD is a tool that limits arm movement and gives the swimmer a target to focus on while doing exercises. The main questions this study will answer are:

* Does using an ECD during certain exercises improve muscle strength?
* Does using an ECD while exercising help with shoulder stability?

Participants will:

* Test their shoulder muscle strength and stability at the beginning of the study.
* Complete 8 exercises as part of their regular dry-land training program for 6 weeks.
* Repeat the same tests after 3 weeks and again at the end of the study.


Eligibility Criteria:
Inclusion Criteria:

* Healthy Volunteer Adolescent Swimmers
* Member of CMSA

Exclusion Criteria:

* Swimmers under the age of 11 years of age.
* Swimmers that are not registered as athletes through United States Swimming.
* Swimmers that are not enrolled in Age Group III, Senior 1, Senior 2, or Senior 3
* Swimmers not attending practice due to an injury (i.e., shoulder, back, etc.).
* Swimmers currently not participating in a dryland program offered through CMSA.